Centiva Capital, LP Spring Works Therapeutics, Inc. Transaction History

Centiva Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$24.97 - $34.05 $211,845 - $288,880	8,484 New	8,484 $218,000
Q2 2021 Aug 16, 2021	SELL	$67.45 - $85.63 $879,345 - $1.12 Million	-13,037 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$65.1 - $93.59 $51,819 - $74,497	-796 Reduced 5.75%	13,037 $959,000
Q4 2020 Feb 16, 2021	BUY	$48.36 - $77.92 $452,939 - $729,798	9,366 Added 209.67%	13,833 $1 Million
Q3 2020 Nov 16, 2020	BUY	$36.14 - $51.99 $161,437 - $232,239	4,467 New	4,467 $213,000

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.37B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.